Novartis AG
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Did you know?
Profit margin of 23.9% — that's well above average.
Current Price
$146.57
-0.87%GoodMoat Value
$194.53
32.7% undervaluedProfile
Valuation (TTM)
Market Cap$279.68B
P/E20.66
EV—
P/B6.06
Shares Out1.91B
P/Sales4.94
Revenue$56.58B
EV/EBITDA11.41
Novartis AG (NVS) Stock Analysis
Market Cap$279.68B
Current Price$146.57
P/E Ratio20.66
Forward P/E—
PEG Ratio-2.10
EPS$7.15
Book Value$24.18
P/B Ratio6.06
NVS Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 5.0% FCF growth (CAGR)
Cash vs Debt
Net Debt: 24.0B
Revenue
48.7B
FY19
49.9B
FY20
44.0B
FY21
43.5B
FY22
46.7B
FY23
51.7B
FY24
56.7B
FY25
Net Income
11.7B
FY19
8.1B
FY20
24.0B
FY21
7.0B
FY22
14.8B
FY23
11.9B
FY24
14.0B
FY25
NVS 52-Week Range
$101.87
$163.61
50-Day MA: $152.88200-Day MA: $134.27
Did you know?
Price sits at 72% of its 52-week range.
Novartis AG (NVS) Financial Summary
Novartis AG (NVS) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. The stock currently trades at $146.57 with a market capitalization of $279.68B.
Key valuation metrics include a P/E ratio of 20.66, price-to-book ratio of 6.06, and EPS of $7.15. The company reports a profit margin of 23.9% and return on equity of 29.3%.
NVS Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $279.68B |
| P/E Ratio | 20.66 |
| EPS | $7.15 |
| P/B Ratio | 6.06 |
| P/S Ratio | 4.94 |
| EV/EBITDA | 11.41 |
| Dividend Yield | 2.80% |
| Profit Margin | 23.9% |
| Return on Equity | 29.3% |
| Debt/Equity | 0.77 |
NVS Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $48.68B | $11.73B |
| FY20 | $49.90B | $8.07B |
| FY21 | $43.97B | $24.02B |
| FY22 | $43.46B | $6.96B |
| FY23 | $46.66B | $14.85B |
| FY24 | $51.72B | $11.94B |
| FY25 | $56.67B | $13.98B |
Novartis AG (NVS) Valuation
Based on GoodMoat's DCF model, Novartis AG has a fair value estimate of $194.53. At the current price of $146.57, the stock appears 24.7% undervalued relative to our intrinsic value estimate.
NVS Quality Indicators
Novartis AG maintains a profit margin of 23.9% and an operating margin of 31.1%. Return on equity stands at 29.3%. The current ratio is 1.12. Debt-to-equity ratio is 0.77.
About Novartis AG
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
NVS Free Cash Flow
Novartis AG generated $17.61B in trailing twelve-month free cash flow, representing an FCF yield of 6.30%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
NVS Shares Outstanding
Novartis AG has 1.91 billion shares outstanding at a share price of $146.57, giving it a market capitalization of $279.68B.